Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjh.18290 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Estimating Health State Utilities for IDH-Mutant Diffuse Glioma.
Pharmacoecon Open
September 2025
Acaster Lloyd Consulting Ltd, Lacon House, 84 Theobalds Rd, London, WC1X 8NL, UK.
Background: Isocitrate dehydrogenase-mutant (mIDH) gliomas are malignant central nervous system tumours. After initial resection, patients with mIDH gliomas with favourable prognosis may live without receiving oncologic treatment for years, but ultimately patients will experience recurrence and require radio- and/or chemotherapy (RT/CT). Cost-utility analyses (CUA) can explore the value of treatments that delay recurrence and initiation of RT/CT.
View Article and Find Full Text PDFFDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgery.
Clin Cancer Res
September 2025
United States Food and Drug Administration, Silver Spring, Maryland, United States.
On August 6, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval to vorasidenib (VORANIGO, Servier Pharmaceuticals, LLC) for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 or 2 (IDH1 or IDH2) mutation following surgery including biopsy, sub-total resection, or gross total resection.
View Article and Find Full Text PDFAcute myeloid leukemia: a comprehensive update.
Curr Opin Hematol
August 2025
Hematopoietic Stem Cell Transplantation Program. Hematology Department Pontificia Universidad Católica de Chile Red de Salud Christus UC.
Purpose Of Review: Acute myeloid leukemia (AML) is a biologically diverse disease that has undergone significant transformation in recent years. The rapid pace of discovery in molecular genetics, disease classification, and therapeutic development has reshaped how we approach diagnosis and treatment. This review aims to provide a timely and relevant synthesis of these advances, offering clinicians and researchers an updated perspective on AML as of 2025.
View Article and Find Full Text PDFComparative Analysis of MRI Features and Overall Survival: IDH-Wildtype Diffuse Lower-grade Glioma and Glioblastoma in Adults.
Acad Radiol
September 2025
Department of Radiology, The First Medical Center of Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, China (X.Y., X.M., J.Z., Y.Z., G.L., F.X., C.H., X.L.). Electronic address:
Rationale And Objectives: In depth comparison of imaging features and overall survival (OS) between IDH wild-type diffuse lower-grade glioma and glioblastoma (GB), providing precise guidance for early risk stratification and optimized clinical decision-making.
Materials And Methods: Retrospective inclusion of IDH wild-type glioma patients admitted between January 2017 and January 2024. Patients were classified into GB (histological and molecular) and lower-grade glioma not elsewhere classified (LGNEC) based on fifth edition of the Central Nervous System Tumor Classification Standards.
Functional cortical mapping and structural subcortical anatomy predicts intra-operative speech arrest: a nTMS-tractography study.
Clin Neurophysiol
August 2025
Department of Neurosurgery, King's College Hospital NHS Foundation Trust, London, UK.
Objective: Cortical speech mapping using navigated Transcranial Magnetic Stimulation (nTMS) has a variable positive predictive value (PPV) when compared with intraoperative direct electrical stimulation.
Methods: This is a single centre prospective study of all patients undergoing pre-operative nTMS and tractography (frontal aslant tract (FAT) and arcuate fasciculus (AF)) for awake surgery between October 2018 and November 2023. We reviewed operative notes for speech arrest, collected data on demographics, histopathology and pre-/post-operative language assessment.